1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

Cardio Catch-Up: Gel For Fixing Heart Attacks, ‘Uncaged’ Coronary Stents, And More

 
• By Reed Miller

Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations in the last two months. Part II of this month’s update includes innovative research and development news from smaller companies and research labs that you may have missed.

Anatomy of Human Heart
• Source: Shutterstock

A team of researchers at the University of Manchester in the UK, led by PhD student Katherine King, have developed a biodegradable gel that can be injected into the beating heart after a myocardial infarction to promote the growth of new myocardial tissue.

In a presentation at the British Cardiovascular Society conference in Manchester on 8 June, King’s group described a pro-angiogenic, injectable self-assembling peptide hydrogel (SAPH) that can augment the “sprouting” and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

More from Device Area

FDA And Boston Scientific Face Legal Action Over Spinal Device Safety

 
• By Elizabeth Orr

A patient, Dena Lawler, is suing Boston Scientific and the US FDA over alleged harm from a spinal stimulator device. Lawler claims inadequate regulatory review allowed dangerous modifications to the device, which then caused her pain and other health issues. She is calling for reconsideration of the device approvals.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Harbinger Health Targets High-Mortality Cancers First With AI-Driven MCED Platform

 
• By Shubham Singh

With a projected FDA submission within the next two to three years, Harbinger is prioritizing cancers based on lethality, prevalence, and unmet diagnostic need. Pancreatic and biliary cancers – often diagnosed at late stages and lacking established screening programs – will be among the initial targets.